Richmond Startup Shocks Investors with $5M Deal – What Happens Next Will Astound You!

A breakthrough investment in the telehealth sector marks a significant milestone for Remission Medical, a Richmond-based company specializing in virtual rheumatology care. The company has successfully secured a $5 million investment from Blue Heron Capital, a private equity firm based in Scott’s Addition. This funding represents the largest capital influx for Remission to date and aims to bolster its growth and service offerings.

Founded in 2022 by Blake Wehman, who personally faced challenges in accessing timely rheumatology appointments, Remission Medical was created to streamline the experience for patients with rheumatologic conditions. Wehman’s own experience with rheumatoid arthritis highlighted the often lengthy wait times for specialist referrals, which spurred him to innovate within the healthcare sector.

Initially operating as its own telehealth clinic, Remission Medical has pivoted to a new business model that involves contracting its services to other healthcare providers. This strategic shift has enabled the company to provide virtual consultations, order lab tests, imaging, and prescriptions through existing systems employed by partner clinics. Wehman described this transformative approach as a means to “expand our mission and go and land more business-to-business contracts.”

Over the past two years, Remission Medical has established contracts with eight health systems, including notable affiliations with Sentara and OrthoVirginia. The company now also partners with larger health systems like Louisiana-based Ochsner Health and Pennsylvania-based WellSpan Health. Its revenue model is based on a fee-for-service system charged to these healthcare providers, allowing Remission to monetize its telehealth offering effectively.

The recent funding from Blue Heron Capital will be instrumental in scaling Remission's operations. According to Wehman, a portion of the investment will be directed towards expanding the workforce, specifically adding nurse practitioners and physician assistants. This will enhance the company's capability to serve a growing client base, particularly focusing on independent clinics that offer specialized care.

Blue Heron Capital, co-founded by Tom Benedetti and Andrew Tichenor in 2006, focuses on investment opportunities in “second-tier” markets with companies typically generating $2 million to $10 million in annual revenue. Benedetti noted that the firm’s interest in Richmond-based companies reflects a growing innovation ecosystem within the region. He expressed excitement about the potential for business growth in Richmond, stating, “It appears that it has gotten to the point where, from our perspective, it’s really accelerating.”

The investment in Remission Medical brings Blue Heron’s total funding in the company to approximately $6.2 million, which includes a prior $1.2 million from angel investors. Benedetti emphasized the importance of supporting local businesses as a way to foster innovation and attract talent to the area. “There is a support system here in Richmond that can convince people that growing companies in Richmond is a really great thing to do,” he said. This sentiment highlights the potential for Richmond to become a viable alternative for entrepreneurs typically drawn to larger cities like Washington D.C. or New York.

The new investment will also facilitate the integration of Mark Rausch into Remission’s board of directors. Rausch, an experienced adviser in the healthcare space, is expected to bring valuable insights as part of Blue Heron’s “OA Collaborative,” which pairs operational advisers with companies in which they invest.

With its increasing reach and the recent influx of capital, Remission Medical aims to solidify its position within the telehealth landscape. Wehman stated that the focus is now on growth rather than immediate profitability. “Right now, we just pour all of our profits back into growth,” he explained. This growth-oriented approach, combined with strategic partnerships and investments, sets Remission Medical on a promising trajectory in the evolving healthcare sector.

As telehealth continues to gain traction, particularly in the wake of the COVID-19 pandemic, the adaptability and innovation shown by companies like Remission Medical will be critical in shaping the future of healthcare delivery. By addressing existing inefficiencies in specialist access, Remission is poised to play a pivotal role in improving patient care in the rheumatology field.